Physician profile
Wade Smith
NPI 1730240219
$4,867.80
in general payments reported to CMS, 2019-2025
30 companies · $35.06 in 2025
The $35.06 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,005 · 2020: $284 · 2021: $390 · 2022: $110 · 2024: $43.35 · 2025: $35.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $43.35 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $43.35 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,689.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $204.72 | 2019-2025 | Imfinzi |
| Lilly USA, LLC | $134.40 | 2020-2022 | |
| Amgen INC. | $133.39 | 2019-2021 | |
| Tersera Therapeutics LLC | $62.99 | 2019 | |
| Pfizer INC. | $60.27 | 2020-2021 | |
| Genentech USA, INC. | $59.27 | 2019 | |
| Glaxosmithkline, LLC. | $42.79 | 2020-2024 | Zejula, Jemperli |
| Incyte Corporation | $39.83 | 2020-2021 | |
| Mylan Institutional INC. | $36.65 | 2019 | |
| Heron Therapeutics, INC. | $35.01 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $31.98 | 2021 | |
| Seagen INC. | $28.00 | 2021 | |
| Celgene Corporation | $24.95 | 2019 | |
| Blueprint Medicines Corporation | $24.88 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $24.04 | 2021 | |
| Genzyme Corporation | $23.83 | 2020 | |
| Daiichi Sankyo INC. | $22.77 | 2020 | |
| Puma Biotechnology, INC. | $22.57 | 2019 | |
| Janssen Biotech, INC. | $21.25 | 2021 | |
| Ge Healthcare | $20.67 | 2024 | |
| Beigene USA, INC. | $19.64 | 2020 | |
| Merck Sharp & Dohme LLC | $19.14 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.77 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $14.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.29 | 2021 | |
| Eisai INC. | $14.23 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Emd Serono, INC. | $11.14 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.